Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications

Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications

Author Di Zazzo, Antonio Google Scholar
Roberti, Gloria Google Scholar
Mashaghi, Alireza Google Scholar
Abud, Tulio Batista Autor UNIFESP Google Scholar
Pavese, Daniela Google Scholar
Bonini, Stefano Google Scholar
Abstract Purpose: Chronic use of topical hypotensive therapies in glaucoma patients leads to chronic inflammation of the ocular surface, which decreases the success rate of long-term glaucoma management. The aim of this study is to evaluate the effect of topical palmitoylethanolamide (PEA) (Defluxa((c))), a well-known anti-inflammatory and analgesic agent, in suppressing the ocular surface inflammation associated with the use of hypotensive eye drops. Methods: In a pilot clinical trial, we enrolled 15 glaucomatous patients who received topical PEA (Defluxa) in addition to the current antiglaucoma drugs, while 15 glaucomatous patients did not receive any additional treatment. At 3 different time points (day 0, 15, and 30), signs of ocular surface involvement, adverse events, visual acuity, and intraocular pressure were assessed. Results: Topical PEA (Defluxa) was effective in increasing the Schirmer test (P<0.05) and the tear film breakup time (T-BUT) (P<0.0001), and improving the conjunctival hyperemia (P<0.0001) by day 30, compared to baseline. Compared to control, by day 15, the conjunctival hyperemia score was significantly decreased in the PEA (Defluxa) group (P<0.01), while the T-BUT and the Schirmer Test achieved a significant improvement by day 30 (P<0.05; P<0.01). Discussion: Our data suggests that topical PEA (Defluxa) is a safe, effective, and generally well-tolerated treatment to prevent or suppress ocular surface inflammation attributable to chronic glaucoma treatment.
Keywords palmitoylethanolamide
dry eye
glaucoma
inflammation
ocular surface
antiglaucoma drugs
xmlui.dri2xhtml.METS-1.0.item-coverage New Rochelle
Language English
Sponsor Ministry of Health
Fondazione Roma
Date 2017
Published in Journal Of Ocular Pharmacology And Therapeutics. New Rochelle, v. 33, n. 9, p. 670-677, 2017.
ISSN 1080-7683 (Sherpa/Romeo, impact factor)
Publisher Mary Ann Liebert, Inc
Extent 670-677
Origin http://dx.doi.org/10.1089/jop.2016.0117
Access rights Closed access
Type Article
Web of Science ID WOS:000413275500004
URI https://repositorio.unifesp.br/handle/11600/58302

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account